Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard.

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Return on Equity (ROE): Exact Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.5%, the company may encounter ...

Exact Sciences rose Friday after the Food and Drug Administration approved its next-generation colon cancer detection test, ...

Exact Sciences Cologuard business also received a boost from updated guidelines released by the United States Preventive Services Task Force. The draft recommended colorectal cancer screening ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings ... increasing Cologuard customer satisfaction and brand awareness to all-time highs; receiving ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard. The ...

At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 Earnings ... increasing Cologuard customer satisfaction and brand awareness to all-time highs, receiving ...